<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Scholar Rock Holding Corp — News on 6ix</title>
    <link>https://6ix.com/company/scholar-rock-holding-corp</link>
    <description>Latest news and press releases for Scholar Rock Holding Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/scholar-rock-holding-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c47b78dffbe2df11a35d.webp</url>
      <title>Scholar Rock Holding Corp</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp</link>
    </image>
    <item>
      <title>Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 16, 2026--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open.</description>
    </item>
    <item>
      <title>Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-resubmits-biologics-license-application-bla-to-fda-for-apitegromab-for-treatment-of-children-and-adults-with-spinal-muscular-atrophy-sma</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-resubmits-biologics-license-application-bla-to-fda-for-apitegromab-for-treatment-of-children-and-adults-with-spinal-muscular-atrophy-sma</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from</description>
    </item>
    <item>
      <title>CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/correcting-and-replacing-scholar-rock-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/correcting-and-replacing-scholar-rock-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
      <pubDate>Tue, 03 Mar 2026 20:26:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., March 03, 2026--In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0.76 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024. (instead of Net loss per common share was $0.88 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024.) In the Condens</description>
    </item>
    <item>
      <title>Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-report-fourth-quarter-130000535</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-report-fourth-quarter-130000535</guid>
      <pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., February 10, 2026--Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open.</description>
    </item>
    <item>
      <title>Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-employee-inducement-211500490</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-employee-inducement-211500490</guid>
      <pubDate>Fri, 16 Jan 2026 21:15:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., January 16, 2026--Scholar Rock (NASDAQ: SRRK; the &quot;Company&quot;) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock.</description>
    </item>
    <item>
      <title>Scholar Rock Highlights 2026 Strategic Priorities</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-highlights-2026-strategic-priorities-2026-01-12</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-highlights-2026-strategic-priorities-2026-01-12</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children</description>
    </item>
    <item>
      <title>Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children</description>
    </item>
    <item>
      <title>Scholar Rock to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-upcoming-investor-conferences-2025-11-18</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-upcoming-investor-conferences-2025-11-18</guid>
      <pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children</description>
    </item>
    <item>
      <title>Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-third-quarter-2025-financial-results-and-recent-business</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-third-quarter-2025-financial-results-and-recent-business</guid>
      <pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
      <description>Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics</description>
    </item>
    <item>
      <title>Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-2025-jefferies-global-healthcare-conference-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-2025-jefferies-global-healthcare-conference-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children</description>
    </item>
    <item>
      <title>Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-report-third-quarter-2025-financial-results-november-14-2025-2025-10-23</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-report-third-quarter-2025-financial-results-november-14-2025-2025-10-23</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November</description>
    </item>
    <item>
      <title>FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/fda-issues-complete-response-letter-crl-apitegromab-treatment-patients-spinal</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/fda-issues-complete-response-letter-crl-apitegromab-treatment-patients-spinal</guid>
      <pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
      <description>No other approvability issues cited in CRL Scholar Rock intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent</description>
    </item>
    <item>
      <title>Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/pivotal-sapphire-trial-data-published-lancet-neurology-apitegromab-demonstrated</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/pivotal-sapphire-trial-data-published-lancet-neurology-apitegromab-demonstrated</guid>
      <pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
      <description>First and only muscle-targeted SMA therapy to demonstrate statistically significant, clinically meaningful improvements on the gold-standard HFMSE scale</description>
    </item>
    <item>
      <title>Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-second-quarter-110000963</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-second-quarter-110000963</guid>
      <pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., August 06, 2025--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the second quarter ended June 30, 2025.</description>
    </item>
    <item>
      <title>Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-host-conference-call-discuss-second-quarter-2025-financial-results-and</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-host-conference-call-discuss-second-quarter-2025-financial-results-and</guid>
      <pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab</description>
    </item>
    <item>
      <title>Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-comprehensive-update-2025-annual-cure-sma-research-and-clinical</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-comprehensive-update-2025-annual-cure-sma-research-and-clinical</guid>
      <pubDate>Mon, 23 Jun 2025 04:00:00 GMT</pubDate>
      <description>Oral presentation on the positive Phase 3 SAPPHIRE trial of apitegromab for people living with spinal muscular atrophy (SMA), which demonstrated</description>
    </item>
    <item>
      <title>Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating</guid>
      <pubDate>Wed, 18 Jun 2025 04:00:00 GMT</pubDate>
      <description>Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone</description>
    </item>
    <item>
      <title>Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-participate-46th-annual-goldman-sachs-global-healthcare-conference-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-participate-46th-annual-goldman-sachs-global-healthcare-conference-2025</guid>
      <pubDate>Thu, 05 Jun 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab</description>
    </item>
    <item>
      <title>Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-appoints-rebecca-mcleod-chief-brand-officer-and-us-general-manager-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-appoints-rebecca-mcleod-chief-brand-officer-and-us-general-manager-2025</guid>
      <pubDate>Mon, 02 Jun 2025 04:00:00 GMT</pubDate>
      <description>Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of</description>
    </item>
    <item>
      <title>Scholar Rock to Present at the Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-jefferies-global-healthcare-conference-2025-05-28</link>
      <guid isPermaLink="true">https://6ix.com/company/scholar-rock-holding-corp/news/scholar-rock-present-jefferies-global-healthcare-conference-2025-05-28</guid>
      <pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab</description>
    </item>
  </channel>
</rss>